Announcements Trials
Browse Landscape Eligibility

Clinical Trials

6 trials
RecentStart dateEnrollment
AML × Clear all

Phase

Phase EARLY_PHASE1 2Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 2Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Conditions

Breast Neoplasms 12991Neoplasms 10383Carcinoma, Non-Small-Cell Lung 6796Prostatic Neoplasms 6198Colorectal Neoplasms 5864Lung Neoplasms 5042Multiple Myeloma 3542Pancreatic Neoplasms 3512Neoplasm Metastasis 3480Leukemia, Myeloid, Acute 3469Carcinoma, Hepatocellular 3232Ovarian Neoplasms 3138Melanoma 3120Stomach Neoplasms 3020Lymphoma 2970Head and Neck Neoplasms 2575Recurrence 2528Precursor Cell Lymphoblastic Leukemia-Lymphoma 2485Leukemia 2353Colonic Neoplasms 2317Brain Neoplasms 2293Lymphoma, Non-Hodgkin 2257Rectal Neoplasms 2173Uterine Cervical Neoplasms 2164Glioblastoma 1993Leukemia, Lymphocytic, Chronic, B-Cell 1985Carcinoma, Renal Cell 1897Squamous Cell Carcinoma of Head and Neck 1857Lymphoma, Follicular 1829Esophageal Neoplasms 1786

Interventions

ivosidenib 1Magnesium 114-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT06717958 2025-07-02

PIVOT

Technische Universität Dresden

Phase 2 Recruiting
76 enrolled

AML

NCT06731699 2024-12-17

A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS

Chengdu FenDi Pharmaceutical Co., Ltd.

Phase 1 Recruiting
72 enrolled

AML

NCT03275636 2024-08-07

HAMLET

DKMS gemeinnützige GmbH

Phase 2/3 Completed
98 enrolled

AML

NCT05252572 2022-02-23

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

Zhejiang University

Phase EARLY_PHASE1 Unknown
36 enrolled

AML

NCT05239689 2022-02-15

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

Zhejiang University

Phase EARLY_PHASE1 Unknown
36 enrolled

AML

NCT02418000 2019-03-20

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

Spirita Oncology, LLC

Phase 1/2 Terminated
27 enrolled 32 charts

AML

Data powered by HemOnc (CC BY 4.0) Colophon âš¡